| Objective To evaluated the efficacy and safety of chemotherapy followed by surgery (CS group) and surgery alone (S group) for esophageal cancer.Methods Esophageal cancer published RCTs were searched from pubmed and Vip Date. RCTs were considered high quality if methodological quality score was 3 or more according Jadad standard.Statistical heterogeneity among these RCTs was evaluated by Revman 5.0.Heterogeneity of the included RCTs was tested which was used to select proper effect model to calculate. Publication bias was investigated through visual inspection of funnel plots.Results 11 RCTs included 2911 cases with esophageal cancer were selected. Compared with S group, CS group significantly increased 3-year,5-year overall survival rate of esophageal cancer. The odds ratio(OR) was1.63( 95%CI: 1.27~2.10, P= 0.0002 )for 3-year, overall survival,1.57(95%CI: 1.31~1.88 ,P< 0.00001 =for 5-year overall survival, and the total OR of postoperative complication in CS group was 1.01 (95%CI: 0.85~1.20 ,P= 0.91 ).Inspection of the funnel plots for all outcome measures did not reveal evidence of publication bias.Conclusion Neoadjuvant chemotherapy and surgery improves 3-year,5-year overall survival rate of esophageal cancer, but doesn't reduce the postoperative complication. |
